Previous 10 | Next 10 |
Summary Clinical trial momentum within the Melanoma diagnostics and treatment paradigm is gaining steam. Immunocore Holdings plc presents with unique exposure for investors to position at the treatment end of the spectrum. Recent advancements in its investigational compounds are wel...
Summary DMTK's assay menu provides a differentiated offering to examining and diagnosing melanoma, an otherwise complex task. Its clear differentiator within the domain is its pigmented lesion division. It's DermTech Melanoma Test looks to provide a breakthrough in this market. ...
Now available to Arizona patients! Non-invasive Smart Stickers™ that lift skin cells to be tested for select genomic markers associated with melanoma. DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision d...
DermTech ( NASDAQ: DMTK ) is down 35% in Friday morning trading after saying it expects to end 2022 with financial results below its guidance range. The company did not elaborate on how much below that might be. Consensus estimates for the year are as follows: revenue, $18...
DermTech, Inc. (DMTK) Q3 2022 Earnings Conference Call November 03, 2022, 05:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - President and CEO Kevin Sun - CFO Conference Call Participants Thomas Flaten - Lake Street Capital ...
DermTech press release ( NASDAQ: DMTK ): Q3 GAAP EPS of -$0.96 beats by $0.03 . Revenue of $3.57M (+17.8% Y/Y) misses by $1.1M . Billable sample volume grew 54 percent from the third quarter of 2021 to approximately 18,080. Assay revenue was $3.4 million, u...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its third-quarter 2022 financial results. “We achieved meaningful year-over-year billabl...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, November 3, 2022 at 5:00 p.m. Eastern Time (ET) to discuss th...
DermTech ( NASDAQ: DMTK ) granted one new, non-executive employee non-qualified stock options to buy ~38.78K common shares. The stock options, which have an exercise price of $4 per share, were granted under Inducement Equity Incentive Plan, the company said in an Oct....
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. ...